A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Cancer Clinical Trial

Official title:

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03733990
• Other study ID #: FP2CLI001
• Secondary ID: 2018-002732-24
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 3, 2018
• Est. completion date: October 31, 2023

Study information

• Verified date: November 2023
• Source: Faron Pharmaceuticals Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. completion date: October 31, 2023
• Est. primary completion date: September 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Subjects must meet all of the following inclusion criteria to be eligible for participation

in the clinical trial:

1. Written Informed Consent

2. Aged = 18 years male or female

3. Tumour sample should be collected during screening period. If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III

4. Life expectancy > 12 weeks

5. Histologically confirmed advanced (inoperable or metastatic) malignancies without

standard therapeutic options available:

• Hepatocellular carcinoma
• Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma
• Colorectal adenocarcinoma
• Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer
• Pancreatic ductal adenocarcinoma
• Immunotherapy (IO) refractory cutaneous melanoma (progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)
• Uveal melanoma in Parts II and III
• Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III
• ER+ breast cancer in Parts II and III
• Anaplastic thyroid cancer in Parts II and III

6. ECOG performance status 0 or 1

7. Measurable disease in Parts II and III

8. Adequate bone marrow, liver and kidney function defined as Blood white blood cell = lower limit of normal Blood neutrophil count = 1x10(9)/L Blood platelet count = 100x10(9)/L, for HCC = 50x10(9)/L Blood haemoglobin = 9.0 g/dL Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula AST = 3 X ULN (= 5 x ULN when HCC or hepatic metastases are present) ALT = 3 X ULN (= 5 x ULN when HCC or hepatic metastases present) Bilirubin = 1.5 X ULN Albumin = 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.

9. Women of child-bearing potential must have a negative pregnancy test in serum prior to trial entry

10. Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment Exclusion Criteria;

1. Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration

2. Any immunotherapy within preceding 6 weeks from the first IMP administration

3. Investigational therapy or major surgery within 4 weeks from the date of consent

4. Active clinically serious infection > Grade 2 NCI-CTCAE version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent

5. Brain metastases

6. Subject has not recovered from the previous therapies to Grade = 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade = 2 alopecia, neuropathy or thyroid disorders)

7. Pregnant or lactating women

8. History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse

9. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial

10. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment

11. Confirmed human immunodeficiency virus infection

12. Symptomatic cytomegalovirus infection

13. Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)

14. The subject requires systemic corticosteroid or other immunosuppressive treatment

15. Subjects with organ transplants

16. Subjects in dialysis

17. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit

18. Subject is unwilling or unable to comply with treatment and trial instructions

19. Subjects with known hypersensitivity to the IMP or any of the pharmaceutical ingredients Specific Additional Exclusion Criteria for Hepatobiliary Cancers

1. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry)

2. Hepatic encephalopathy

3. Ascites refractory to diuretic therapy

4. Child-Pugh score = 7

Related Conditions & MeSH terms

• Cancer

Intervention

Biological:
• FP-1305 (bexmarilimab)
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Locations

Country	Name	City	State
Finland	Clinical Research Institute HUCH Ltd	Helsinki
Finland	Oulu University Hospital	Oulu
Finland	Tampere University Hospital	Tampere
Finland	Turku University Hospital	Turku
France	The Institut Gustave Roussy	Villejuif
Netherlands	Erasmus University Medical Center Rotterdam	Rotterdam
Spain	START Madrid - CIOCC Hospital HM Sanchinarro	Madrid
United Kingdom	Queen Elizabeth Hospital Birmingham	Birmingham
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	The Royal Marsden NHS Foundation Trust	Sutton	Surrey
United States	The University of Texas Health Science Center at San Antonio	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Faron Pharmaceuticals Ltd

Countries where clinical trial is conducted

United States,  Finland,  France,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicities (DLT) in the trial subjects.	Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects.	Up to one year
Primary	Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)	Number of adverse events and serious adverse events. Adverse events are collected, graded and reported according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.	Up to six years
Primary	The response (ORR, CBR and irORR) to the treatment.	The objective response rate (ORR), clinical benefit rate (CBR) and immune-related ORR (irORR) to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1. Results from each tumour type, dose level and dosing frequency will be reported separately.	Up to six years